{
    "clinical_study": {
        "@rank": "167998", 
        "arm_group": {
            "arm_group_label": "spironolactone", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we\n      demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis\n      (HD) patients. In the present study, we assess whether low-dose spironolactone treatment\n      reduces the high incidence of cardio- and cerebrovascular (CCV) morbidity and mortality in\n      HD patients. The investigators' hypothesis is that aldosterone receptor blockade by\n      spironolactone reduces the risk of both CCV morbidity and death among HD patients."
        }, 
        "brief_title": "Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients", 
        "condition": "End-stage Renal Failure", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hemodialysis patients undergoing 4-hour-long HD thrice a week for at least 2 years\n\n          -  With an average serum potassium level (immediately before dialysis on the first day\n             of the week) of <6.5 mEq/l over the previous 2 months\n\n          -  With a 24-hour urine output of <500 ml\n\n        Exclusion Criteria:\n\n          -  A history of noncompliance\n\n          -  Unstable vascular access\n\n          -  Hypotension\n\n          -  Hepatic failure\n\n          -  Active cancer\n\n          -  Any life-threatening disease other than ESRD"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "157", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01687699", 
            "org_study_id": "dohas01"
        }, 
        "intervention": {
            "arm_group_label": "spironolactone", 
            "intervention_name": "Spironolactone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Spironolactone"
        }, 
        "keyword": [
            "cardiovascular event", 
            "hemodialysis", 
            "spironolactone"
        ], 
        "lastchanged_date": "September 14, 2012", 
        "link": {
            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19342857"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Shizuoka", 
                    "country": "Japan", 
                    "zip": "424-0053"
                }, 
                "name": "Shibukawa Clinic"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "cardio- and cerebrovascular events"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687699"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dialysis Outcomes Heart Failure Aldactone Study Group", 
            "investigator_full_name": "Yoshihiro Matsumoto", 
            "investigator_title": "MD., PhD.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "death from all causes"
        }, 
        "source": "Dialysis Outcomes Heart Failure Aldactone Study Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dialysis Outcomes Heart Failure Aldactone Study Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}